By: IPP Bureau
Last updated : April 25, 2026 8:07 am
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
In a move aimed at strengthening industry–academia collaboration in India’s pharmaceutical sector, National Institute of Pharmaceutical Education and Research (NIPER) Hajipur has signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim India Pvt. Ltd. to advance collaborative research and accelerate healthcare innovation.
The agreement was formalised at Kartavya Bhawan in New Delhi in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® open science platform, enabling broader scientific exchange and supporting innovation-driven research. The collaboration is expected to enhance research capacity at NIPER Hajipur, offer hands-on training opportunities for students, and generate early-stage proof-of-concept data that can be scaled into preclinical development.
The initiative will leverage a resource-efficient and integrated research framework to translate scientific discoveries into viable therapies, with the aim of positioning NIPER Hajipur as a key hub for translational pharmacology.
Highlighting the significance of the collaboration, Manoj Joshi underscored the role of academia–industry partnerships in bridging the gap between research and commercialisation and in driving innovation. The alliance is expected to foster synergy between academia and industry, support the development of next-generation therapies, and contribute to building a robust, innovation-led healthcare ecosystem in India.